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Abstract: The consistent technical and conceptual progress in the
study of the microbiota has led novel impulse to the research for
therapeutical application of probiotic bacteria in human patholo-
gies, such as inflammatory bowel disease (IBD). Considering the
heterogenous results of probiotics in clinical studies, the model of
translational medicine may lead to a more specific and efficacious
utilization of probiotic bacteria in IBD. In this regard, the selection
and utilization of appropriate experimental models may drive the
transition from pure in vitro systems to practical clinical applica-
tion. We developed a simple and reproducible ex vivo organ culture
method with potential utilization for the evaluation of probiotic
bacteria efficacy in IBD patients.
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Probiotic bacteria have been largely proposed in differentpathologic conditions and their use has increased in the
last decades.1 Nonetheless, solid evidence for their use in
specific pathologic conditions is limited, and too often their
utilization is much more driven by commercial suggestion
than by scientific proofs. Recently, probiotic bacteria have
been proposed in the setting of inflammatory bowel diseases
(IBD).2 Indeed, the increased comprehension of the com-
plex pathogenesis of the disease, together with the growing
knowledge of the microbiota composition and functions,
highly stimulated by the novel culture-independent
genomic-based techniques (ie, next-generation sequenc-
ing), have consistently pushed forward the idea of the
influence of the microbiota in IBD onset and development.3
In fact, experimental and clinical evidence that microflora
alteration may not only be a consequence of inflammation,
but may have an important causative role in IBD course,
are mounting.4,5 Those findings are stimulating the research
on potential therapeutical application of microbiota
manipulation, by reduction of potential proinflammatory
bacterial species (by antibiotics), stimulation of endogenous
bacteria with anti-inflammatory properties (by prebiotics),
administration of specific bacteria with favorable profile
(probiotics) or of their products (postbiotics), or, lately,
with the transfer of the whole fecal echosystem from a
healthy donor (fecal transplantation).
In IBD, the therapeutic application of probiotic bac-
teria has been so far more convincing in experimental
models than in clinical setting.6 The reason probably resides
primarily in the complexity of human disease, which is not
easily reproducible in experimental models. Consequently,
animal and experimental models may be at best repre-
sentative of specific aspects of the human condition, which
is characterized by a complex interplay of genetic and
environmental factors, as well as by the involvement of
different molecular pathways. In the simplification of an
experimental model, many therapeutic approaches may
prove to be efficacious but may not be directly applicable in
clinical setting. Moreover, even though clinical studies of
probiotics application in IBD are growing, they are still
characterized by a consistent heterogeneity in the design,
bacterial species used, dosages, time of treatment, and
endpoints. For the design of future trial, the correct selec-
tion of the probiotic bacteria to be tested seems to be of
particular relevance, as a bacterial species may present
peculiar characteristics that may suggest the application for
therapeutic purposes only in a specific disease.
Indeed, the rational and scrupulous development of
combined in vitro/in vivo studies seems crucial for the
proposal and implementation of probiotic bacteria appli-
cation as therapeutic option in specific pathologic con-
dition, including IBD. In this setting of translational med-
icine, the role of appropriate “transitional” models (ie,
experimental models more representative of the in vivo
situation than the traditional in vitro systems, which may
favor and guide the transition to a specific clinical appli-
cation in human) could be of great relevance. In accordance
with that, we developed a simple and reproducible ex vivo
experimental model to evaluate the adhesion and the
mucosal effect of bacterial species administration on nor-
mal and pathologic intestinal mucosa.
EX VIVO ORGAN CULTURE EXPERIMENTAL
MODEL
A synthetic scheme of the procedure of the method is
represented in Figure 1. Bioptic samples are collected dur-
ing colonoscopy from normal (proximal and distal seg-
ment) and pathologic colon (ie, adenomatous polyps,
ulcerative colitis patients). Biopsies are then washed 2 times
in fresh phosphate buffered saline (PBS) solution and
weighed to avoid consistent difference among samples. For
the evaluation of bacterial adhesion, bioptic specimens are
put in a 2-mL Falcon tube with 200mL of Roswell Park
Memorial Institute (RPMI) media, with the addition of
20 mL (1:10) of a solution of different probiotic for-
mulations in PBS. As a negative control, biotic samples are
put in RPMI media with 1:10 of PBS without any probiotic
bacteria. The reaction is incubated at 371 for 2 hours, and
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then the bioptic samples are collected and washed 2 times in
fresh PBS to remove nonadherent bacteria, and finally put
in RNA Later solution (Qiagen, Valencia, CA) until further
processing. Total DNA is extracted by Qiamp DNA mini
kit (Qiagen) according to manufacturer instruction. All the
DNA samples are checked by spectrophotometer Gene
Quant pro RNA/DNA calculator (Amersham Pharmacia
Biotech, Piscataway, NJ) for concentration and purity, and
the solutions are brought at the same concentration. Real-
time PCR is performed with specific primers for the different
probiotics species (already described in the literature), and
adherent probiotic bacteria are quantified in a semi-
quantitative manner by a relative ratio to the lowest detected
sample. PCR reactions are performed in a total volume of
20mL in an iCycleriQ detection system (Bio-Rad Labo-
ratories Inc., Hercules, CA), with 16mL of SYBR Green
PCR Supermix (Bio-Rad Laboratories Inc.) and 4mL of
target DNA. For every set of primers, the original cycle
conditions are generally maintained. House-keeping genes
(b-actin and GADPH) were used for normalization of the
values. After reactions, PCR products are run on a 2%
agarose gel with ethidium-bromide staining for visualization.
For the evaluation of mucosal effect of probiotic
bacteria, we apply the same model to test the expression of
proinflammatory and anti-inflammatory cytokines, with
few variations. In particular, bioptic samples are incubated
for a longer time (6 h) to evaluate variation in mRNA
production after the incubation, and we add to the RPMI
media with bioptic samples a 1:10 solution of probiotic
conditioned media, prepared according to a procedure
already described in the literature,7 or PBS alone for neg-
ative controls. We set the incubation time to 6 hours as
longer time resulted in contamination of the reaction and
degradation of RNA, with a consistent reduction of
expression of the house-keeping genes. After incubation,
total RNA is extracted by RNAeasy miniprep kit (Qiagen),
cDNA synthesized by GeneAmp RNA PCR kit (Applied
Biosystems, Foster City, CA), and mRNA for specific
cytokines quantified by real-time PCR and normalized to
house-keeping gene concentration, as already described
above.
PRELIMINARY RESULTS: PROBIOTIC MUCOSAL
ADHESION
To test mucosal adherence of different probiotic bac-
teria, mucosal biopsies from normal proximal and distal
colon, taken from 6 subjects in whom colonoscopy did not
show macroscopic or microscopic evidence of pathology,
were incubated, according to the aforementioned described
protocol, with a commercially available multispecies pro-
biotic compound. Analyzing the mucosal adhesion of 3
representative bacteria of the formulation, we observed that
different bacterial species adhered in a peculiar manner to
the proximal and the distal colonic specimens. In particular,
after incubation, a consistent adhesion of Streptococcus
thermophilus and Bifidobacterium infantis was observed,
whereas Lactobacillus acidophilus was not detectable either
in the proximal or in the distal colonic segments. Consid-
ering relative segmental adhesion, we found a significantly
higher adhesion of B. infantis to the proximal compared
with the distal specimens, and a similar trend for S. ther-
mophilus, even though to a lesser degree (Fig. 2). Those data
support the hypothesis that probiotic species may adhere in
a peculiar way to the intestinal mucosa, and an exper-
imental model that can assess that property could be of
great relevance for the specific selection of bacterial species
for utilization in pathologic conditions.
DISCUSSION
The investigation of probiotic bacteria in clinical set-
tings has been influenced by the technical and conceptual
revolution of the microbiota field. Nowadays, 2 different
approaches are leading the research of possible clinical
application of probiotics. On one hand, the accurate anal-
ysis of microbiota alteration in pathologic versus physio-
logical conditions, made possible by the novel sequencing
techniques available, is leading to the identification, and to
the possible test, of bacterial species with a possible specific
role in the prevention of the pathologic conditions inves-
tigated. However, the fascinating approach of the devel-
opment of those novel probiotic species has several limi-
tations. In fact, different composition in microbiota
between patients and normal controls may not necessarily
imply a causative role of the bacteria for the pathologic
condition. Moreover, as the putative bacteria have not been
usually used as a supplement in humans before, the iden-
tified species would need a thorough in vitro and in vivo
characterization in terms of safety, efficacy, and stability
both in drug formulation and in the gastrointestinal tract.
On the other hand, the other branch of research is focusing
on the in-deep characterization of the properties of pro-
biotic bacteria already known and diffuse in the market,
FIGURE 1. A schematic representation of the ex vivo organ culture technique. For a detailed description refer to the text.
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such as L. rhamnosus GG, which represents the most
studied species in this class of bacteria. In this setting, the
aim of the research is to evaluate specific characteristic of
the bacteria with a potential application in particular clin-
ical situation, with the advantage of the major compre-
hension of the general characteristics and of the safety
profile of the bacteria. In fact, as those bacteria are already
in use from quite a long time, drug formulations have been
already developed and the safety profile is generally
favorable. Nonetheless, utilization of such products is often
empirical and unspecific, and appropriate evaluation in
specific clinical indication is warranted. In both methods of
research, the preclinical evaluation and selection of specific
probiotic species with specific features may increase and
lead the utilization of such bacteria in appropriate clinical
settings.
For this purpose, we developed and described an
ex vivo organ culture experimental model. The present
method has not been directly validated so far, but, for the
evaluation of bacterial adhesion, indirect proof of correla-
tion with the in vivo adhesion is available. In fact, we have
previously demonstrated an in vivo reduction of concen-
tration of total mucosal adherent bacteria in adenomatous
polyps compared with adjacent normal mucosa, together
with an increment of production of antibacterial molecules,
such as a-defensins. A similar reduction of bacterial con-
centration in polyp mucosa was observed in the ex vivo
experimental model, when bioptic samples were incubated
with a multistrain probiotic formulation.8 Moreover, a
similar pattern of adhesion of the 3 bacteria, tested in the
present paper in normal human colon, was observed in vivo
in a mouse model of spontaneous ileitis (ie, SAMP1/YitFc).
In fact, after 6 weeks of supplementation at high dose with
the multiple probiotic formulation, only S. thermophilus
and B. infantis, but not L. acidophilus, were detectable at
mucosal level in the terminal ileum of mice, despite the
latter bacteria being consistently detected in DNA extracted
from feces.9
The potential usefulness of the model for the evalua-
tion of mucosal effect of the tested bacteria remains to be
determined, and comparison with experimental and in vivo
findings for cytokines expression after probiotic admin-
istration are currently ongoing. One could speculate that, as
in the ex vivo model the bioptic samples are simply put in
incubation with probiotic conditioned media, direct para-
cellular stimulation of the lamina propria compartment by
probiotic media may occur. For that reason, the model may
not be fully representative of the in vivo situation, where
the epithelial cells represent the main interface between
luminal content and subepithelial compartment. To address
that point, comparison with the effect of probiotic on cells
of the different intestinal compartments may help in the
interpretation of data from the experimental model. To
better mimic the in vivo situation, an experimental model in
FIGURE 2. A and B, Mucosal DNA concentration of Bifidobacterium infantis and Streptococcus thermophilus in the proximal and the distal
colonic biopsies after incubation with multiple probiotic compound. Lactobacillus acidophilus was not detectable. Data are expressed as
a relative ratio to the lowest detectable sample. C, Relative increment in proximal versus distal colonic specimens in the single individual.
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which surgical specimens are cultured and polarized has
been recently described.10 Compared with the model
described in the present paper, such a model offers the
advantage of a more detailed study of the immune mucosal
effect of different stimuli (ie, different probiotic bacteria), in
particular for the utilization of a cave cylinder that delim-
ited the area of stimulation on the apical face of the
mucosa. In contrast, such a model is basically more com-
plex and necessitates surgical mucosal explants that are less
easily available compared with bioptic specimens.
CONCLUSIONS
In the present paper, we have described an exper-
imental method that is potentially applicable in every lab-
oratory, which do not need complex procedures and is of
limited cost. The application and the potential limitation of
this experimental model are still to be fully explored, but
with that simple and reproducible method the adhesion of
different bacterial species to normal and pathological colon
may be tested. As different probiotic species adhere in a
peculiar way to normal and pathological colon, as well as in
different segments of the normal colon, such a method may
be useful for the selection of bacteria for the treatment of
specific pathologic situation. For instance, probiotic bac-
teria with an elective adhesion to the distal colon may be
particularly indicated in the distal ulcerative colitis, whereas
a species with a widespread adhesion to the whole colon
may be more appropriate in pancolitis. Studies for the
evaluation of this method for the effect of the bacteria on
mucosal cytokines expression and production are ongoing.
The correct application of translational medicine, with
the appropriate utilization of specific experimental models
for the selection of bacterial species with well-described
characteristics for specific clinical situation, will hopefully
lead to a more tailored and efficacious utilization of pro-
biotic bacteria in the field of IBD treatment.
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